Research summary

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ), developed as a pharmacological "exercise mimetic" studied for inducing metabolic adaptations resembling those of physical activity, primarily through ERRα-driven upregulation of PGC-1α and fatty-acid oxidation.

In mouse studies, SLU-PP-332 increased the proportion of oxidative type IIa skeletal muscle fibers and improved exercise endurance, alongside increased energy expenditure and reduced fat mass. Researchers have flagged pan-ERR activation as carrying potential off-target risks, including cardiac hypertrophy and liver toxicity signals, that have not yet been fully characterized. All published evidence is preclinical; no human clinical trial data were found.

Sources: bioRxiv, 2022; ACS Chemical Biology, 2022; Washington University Medicine research, 2024. Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.

Decoding the Benefits

Shifted muscle fiber composition toward the more fatigue-resistant, oxidative type — a hallmark of endurance training — without any actual exercise.
Paired with reduced fat mass and higher energy expenditure in the same studies.